關于阿斯利康<\/u><\/b><\/p> \n
阿斯利康是一家科學至上的全球性生物制藥企業，專注于研發、生產及營銷處方類藥品，重點關注腫瘤、罕見病、心血管、腎臟及代謝、呼吸和免疫等疾病領域。總部位于英國劍橋的阿斯利康業務遍布100多個國家，創新藥物惠及全球數百萬患者。更多信息，請訪問www.astrazeneca.com<\/a>。<\/p> \n 關于阿斯利康中國<\/u><\/b><\/p> \n 自1993年進入中國以來，阿斯利康堅持科學至上，注重創新，以滿足中國不斷增長的健康需求，實現"開拓創新，造福病患，成為中國最值得信賴的醫療合作伙伴"這一宏偉愿景。阿斯利康的中國總部位于上海，并分別在北京、廣州、無錫、杭州、成都建立區域總部。公司在江蘇無錫和泰州投資建有生產基地，并在無錫建立了中國物流中心。在中國，阿斯利康的業務重點主要集中在中國患者需求最迫切的治療領域，包括呼吸、心血管、代謝、腫瘤、消化、腎臟及罕見病。2017年，中國健康物聯網創新中心在無錫落地，旨在探索創新的健康物聯網診療一體化全病程管理解決方案。同年，阿斯利康與國投創新合資成立迪哲（江蘇）醫藥有限公司，以加快本土新藥研發步伐。2019年，阿斯利康宣布與無錫合作共建無錫國際生命科學創新園，匯聚全球智慧，造福中國患者。2020年，阿斯利康宣布支持"互聯網醫院"項目。2021年，阿斯利康正式升級位于上海的全球研發中國中心，并與中金資本聯合發起阿斯利康中金醫療產業基金。<\/p> \n 聲明 參考文獻<\/b><\/p> \n 1. Paolo Ghia, Andrzej Pluta, Ma?gorzata Wach, et al. Acalabrutinib Versus Investigator's Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere 6(12):p e801, December 2022.<\/span><\/p> <\/td> \n <\/tr> \n 2. Yang, Shenmiao, Huang, Haiwen, Zhou, Keshu, et al. EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED\/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1\/2 TRIAL. HemaSphere. 2023.<\/span><\/p> <\/td> \n <\/tr> \n 3. https:\/\/www.cancer.gov\/types\/leukemia\/patient\/cll-treatment-pdq#_1.<\/span><\/p> <\/td> \n <\/tr> \n 4. 《慢性淋巴細胞白血病\/小淋巴細胞淋巴瘤診療指南（2022年版）》<\/span><\/p> <\/td> \n <\/tr> \n 5. 朱華淵, 等. CLL-IPI評分系統在中國慢性淋巴細胞白血病患者中的預后評估價值[J]. 中華血液學雜志.2018;39(5):392-7<\/span><\/p> <\/td> \n <\/tr> \n 6. NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma<\/span><\/p> <\/td> \n <\/tr> \n 7. 《中國臨床腫瘤學會（CSCO）淋巴瘤診療指南（2023版）》<\/span><\/p> <\/td> \n <\/tr> \n 8. Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022 Jan 11;21(1):4. doi: 10.1186\/s12938-021-00973-6. PMID: 35016695; PMCID: PMC8753864.<\/span><\/p> <\/td> \n <\/tr> \n 9. National Cancer Institute. Cancer stat facts: leukemia — chronic lymphocytic leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed May 2022.<\/span><\/p> <\/td> \n <\/tr> \n 10. American Cancer Society. What is chronic lymphocytic leukemia. https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/what-is-cll.html. Accessed May 2022.<\/span><\/p> <\/td> \n <\/tr> \n 11. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version. https:\/\/www.cancer.gov\/types\/leukemia\/patient\/cll-treatment-pdq. Accessed May 2022<\/a>.<\/span><\/p> <\/td> \n <\/tr> \n 12. Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia (ASCEND): a randomized phase 3 trial. J Clin Oncol. 2020;25: 2849-2861. doi: 10.1200\/JCO.19.03355.<\/span><\/p> <\/td> \n <\/tr> \n 13. ClinicalTrials.gov. Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies. NCT identifier: NCT03932331. https:\/\/www.clinicaltrials.gov\/study\/NCT03932331?term=NCT03932331&rank=1. Accessed August 2023.A<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n <\/p>"];
$("#dvExtra").html(content_array[0]);})();
<\/i>部分研究中的藥品用法尚未在中國獲批適應癥，阿斯利康不推薦任何未被批準的藥品使用。<\/i><\/p> \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n